Medpace Holdings, Inc. $MEDP Shares Sold by CreativeOne Wealth LLC

CreativeOne Wealth LLC reduced its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 61.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,483 shares of the company’s stock after selling 2,328 shares during the quarter. CreativeOne Wealth LLC’s holdings in Medpace were worth $465,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Jefferies Financial Group Inc. lifted its holdings in shares of Medpace by 20.1% during the 2nd quarter. Jefferies Financial Group Inc. now owns 25,253 shares of the company’s stock valued at $7,926,000 after acquiring an additional 4,218 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Medpace by 13.7% during the second quarter. American Century Companies Inc. now owns 12,717 shares of the company’s stock worth $3,991,000 after purchasing an additional 1,529 shares in the last quarter. Nemes Rush Group LLC boosted its position in shares of Medpace by 8.3% in the second quarter. Nemes Rush Group LLC now owns 628 shares of the company’s stock worth $197,000 after buying an additional 48 shares during the period. Heron Bay Capital Management grew its stake in shares of Medpace by 0.3% in the second quarter. Heron Bay Capital Management now owns 19,640 shares of the company’s stock valued at $6,164,000 after buying an additional 57 shares in the last quarter. Finally, AXQ Capital LP acquired a new stake in shares of Medpace in the second quarter valued at about $217,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

MEDP opened at $599.50 on Friday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $626.26. The stock has a market capitalization of $16.89 billion, a PE ratio of 41.92, a P/E/G ratio of 2.67 and a beta of 1.42. The firm’s fifty day moving average price is $560.60 and its 200 day moving average price is $444.37.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 42,392 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $615.52, for a total transaction of $26,093,123.84. Following the sale, the chief executive officer directly owned 732,210 shares of the company’s stock, valued at approximately $450,689,899.20. This represents a 5.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Kevin M. Brady sold 3,000 shares of the firm’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the transaction, the chief financial officer owned 6,000 shares in the company, valued at $3,542,100. This trade represents a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 317,597 shares of company stock worth $189,967,248. 20.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MEDP. Mizuho upped their price target on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a report on Friday, October 24th. Jefferies Financial Group upped their target price on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. TD Cowen raised their price target on shares of Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday, October 24th. Truist Financial set a $555.00 price target on shares of Medpace in a research note on Monday, October 27th. Finally, Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $487.18.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.